Peptides displayed by HLA for use in immunotherapy against different types of cancers
Inventors
Hannen, Ricarda • Hukelmann, Jens • Koehler, Florian • Kowalewski, Daniel Johannes • Schuster, Heiko • Schoor, Oliver • Roemer, Michael • Tsou, Chih-Chiang • FRITSCHE, Jens
Assignees
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Publication Number
US-12318407-B2
Publication Date
2025-06-03
Expiration Date
Abstract
The invention relates to a peptide comprising an amino acid sequence selected from the group consisting of (i) SEQ ID NO: 1 to SEQ ID NO: 216, and (ii) a variant sequence thereof which maintains capacity to bind to MHC molecule(s) and/or induce T cells cross-reacting with said variant peptide, or a pharmaceutically acceptable salt thereof.
Core Innovation
The invention describes peptide compositions and immunotherapy approaches centered on the amino acid sequence VLQSLQHEL (SEQ ID NO: 82) provided as a pharmaceutically acceptable salt and, in related aspects, as a pegylated peptide modified with PEG. The disclosed peptide forms include salt variations and can be incorporated into a pharmaceutical composition with a pharmaceutically acceptable carrier and optional immune-related adjuvants.
The invention also describes treating a patient who has cancer by administering a population of activated T cells that kill cancer cells that present a peptide consisting of the amino acid sequence of VLQSLQHEL (SEQ ID NO: 82). The described mechanism is based on cancer cells presenting the specified peptide and activated T cells targeting those peptide-presenting cancer cells, with the cancers selected from a named group.
In additional claimed aspects, activated T cells can be further defined by a T cell receptor (TCR) that binds the specified VLQSLQHEL peptide when presented as a complex with an MHC class I molecule on the cancer cell surface. The invention further recites optional co-administration of adjuvants, including immune modulators and cytokines, with explicit examples including IL-2.
Claims Coverage
The partial claim set includes four independent claims. Three independent claims cover peptide/salt/pegylated peptide embodiments for VLQSLQHEL (SEQ ID NO: 82), and one independent claim covers a cancer treatment method using activated T cells that kill cancer cells presenting that peptide, with cancers selected from an enumerated group.
A peptide consisting of the amino acid sequence VLQSLQHEL (SEQ ID NO: 82) in the form of a pharmaceutically acceptable salt
A peptide is defined by the specific amino acid sequence VLQSLQHEL (SEQ ID NO: 82) and is provided in a pharmaceutically acceptable salt form.
A pegylated peptide consisting of the amino acid sequence of VLQSLQHEL (SEQ ID NO: 82) or a pharmaceutically acceptable salt thereof modified with PEG
A pegylated peptide is defined by VLQSLQHEL (SEQ ID NO: 82) (or a pharmaceutically acceptable salt thereof) and includes PEG modification as part of the pegylated peptide.
A peptide consisting of the amino acid sequence VLQSLQHEL (SEQ ID NO: 82) in the form of a salt
A peptide is defined by the specific amino acid sequence VLQSLQHEL (SEQ ID NO: 82) and is provided in salt form.
A method of treating a patient who has cancer by administering activated T cells that kill cancer cells presenting VLQSLQHEL (SEQ ID NO: 82)
A treatment method administers a population of activated T cells that kill cancer cells that present a peptide consisting of the amino acid sequence VLQSLQHEL (SEQ ID NO: 82), where the cancer is selected from a defined group of cancer types.
Overall, the claim coverage in the partial content is anchored on the specific peptide VLQSLQHEL (SEQ ID NO: 82), including salt and pegylated peptide embodiments, and a cancer treatment method using activated T cells that kill cancer cells presenting that peptide, with cancer selection limited to the enumerated set in the method claim.
Stated Advantages
Not explicitly described in patent.
Documented Applications
Treating a patient who has cancer using activated T cells that kill cancer cells presenting VLQSLQHEL (SEQ ID NO: 82), with cancer types selected from the group including acute myeloid leukemia, breast cancer, glioblastoma, melanoma, non-Hodgkin lymphoma, non-small cell lung cancer, renal cell carcinoma, and uterine endometrial cancer.
Pharmaceutical compositions containing VLQSLQHEL (SEQ ID NO: 82) as a pharmaceutically acceptable salt and, in related aspects, pegylated forms modified with PEG, optionally including a pharmaceutically acceptable carrier and optional adjuvants.
Interested in licensing this patent?